Thank you. Updated. This was meant to be a rough
Post# of 148181
(Total Views: 536)
Posted On: 08/13/2020 1:12:32 PM
Re: invisioner #49193
Thank you. Updated. This was meant to be a rough draft/starting point.
A therapeutic has shown efficacy against COVID. Its called Leronlimab, have you heard of it? If not read on.
Cytodyn has recently submitted top line data from a double blinded, placebo controlled study to the FDA for Leronlimab. Leronlimab showed statistically significant improvement in NEWS2 score, a widely accepted metric for measuring the progression of COVID into the severe/critical phase. (p value .02)
In this study, Leronlimab increased the number of patients who showed clinical improvement in their NEWS2 score, by 250%.
In addition, Leronlimab showed anecdotal evidence of efficacy in the reducing mortality in the severe/critical population in over 70 emergency use indication patients.. A phase 3 trial is ongoing for this population, with an interim analysis of the data due in the coming weeks.
Why haven’t you heard about it? Because Cytodyn is a small biotech company, that does not yet have an FDA approval in any indication. Don’t let that dissuade you, however as Leronlimab has shown early indication of efficacy in a whole host of diseases and the company is actively running trials in several of them.
We need your help to get the word out, so that this treatment can get to market and start saving lives. Please research Cytodyn, and reach out to the company for more information.
www.cytodyn.com
Nader Pourhassan CEO npourhassan@cytodyn.com
Scott Kelly, MD CMO skelly@cytondyn.com
A therapeutic has shown efficacy against COVID. Its called Leronlimab, have you heard of it? If not read on.
Cytodyn has recently submitted top line data from a double blinded, placebo controlled study to the FDA for Leronlimab. Leronlimab showed statistically significant improvement in NEWS2 score, a widely accepted metric for measuring the progression of COVID into the severe/critical phase. (p value .02)
In this study, Leronlimab increased the number of patients who showed clinical improvement in their NEWS2 score, by 250%.
In addition, Leronlimab showed anecdotal evidence of efficacy in the reducing mortality in the severe/critical population in over 70 emergency use indication patients.. A phase 3 trial is ongoing for this population, with an interim analysis of the data due in the coming weeks.
Why haven’t you heard about it? Because Cytodyn is a small biotech company, that does not yet have an FDA approval in any indication. Don’t let that dissuade you, however as Leronlimab has shown early indication of efficacy in a whole host of diseases and the company is actively running trials in several of them.
We need your help to get the word out, so that this treatment can get to market and start saving lives. Please research Cytodyn, and reach out to the company for more information.
www.cytodyn.com
Nader Pourhassan CEO npourhassan@cytodyn.com
Scott Kelly, MD CMO skelly@cytondyn.com
(2)
(1)CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼